Home    中文 | English

Milestones

  • 1998

    Registered in Tai-Chung City with capital of NT$2 millions.

  • 2000

    Moved to Taipei Chong shan N. Road office and increased capital to NT$18 millions. Entered co-developed agreement with Genovate Biotechnology. Entered distribution agreement with Dupont Pharmaceuticals.

  • 2001

    Entered distribution agreement with 3M Pharmaceuticals. Increased capital to NT$22 millions.

  • 2003

    Signed exclusive distribution agreement with Biogen Idec, a US company for conducting the first biologics clinical trial.

  • 2004

    Changed ownership to Limited Company with the same capital size.

  • 2005

    Signed exclusive distribution agreement with Vitrolife,a Swedish company for its lung transplant preservative.

  • 2007

    Acquired Apex Pharma and increase capital size to NT$100M.

  • 2008

    Distributed SAM Medical Products for emergency care.

  • 2009

    Distribute 3 River Pharmaceuticals long acting Amphotericin.

  • 2010

    Entered co-developing agreement with Raptor Therapeutics to conduct Convivia phase II b trial for future marketing and OEM.

  • 2011

    Entered exclusive agreement with AMDL Diagnostics Inc. for DR-70® tumor marker ELISA test for Taiwan.

  • 2012

    Entered exclusive agreement with Baxter Healthcare for Anti-adhesion medical device.

  • 2013

    Entered technology transfer agreement with AMDL Inc. to manufacture DR-70® in Taiwan and supply to Asia-Pacific countries.

  • 2014

    Moved to Current Nei-hu office and increased capital to NT$130 millions. Granted DR-70® Taiwan manufacturing license. Entered distribution agreement with iStat for its Cervi-M DNA Methylation test for Cervical Cancer. Increased capital to NT$170 millions. First export Taiwan version DR-70 to India.

  • 2015

    Received Taiwan FDA award as Good Distribution Practice company.

    Certified by TRACE and received clearance of anti bribery Compliance Solutions.

  • 2016

    Received ISO13495:2003 Medical Device Certification by SGS.

    Establishing Uni Pharma in-house laboratory for new neurological bio-markers R&D and anti-cancer drug blood concentration monitoring test.